European Commission approves Celltrion’s SteQeyma® (CT-P43), a biosimilar to Stelara® (ustekinumab), for the treatment of multiple chronic inflammatory diseases

Contributed by: Business Wire

Logo

Tags

Health

Other Health

Clinical Trials

General Health

Pharmaceutical

Biotechnology

Celltrion

More Like This

Celltrion Receives EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra® (tocilizumab)

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

PR Newswire associated0

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

Celltrion receives European Commission approval of Omlyclo® (CT-P39), the first and only omalizumab biosimilar approved in Europe

Celltrion showcases promising results in phase III study for CT-P47, a biosimilar candidate of RoActemra® (tocilizumab) in patients with rheumatoid arthritis (RA) at EULAR 2024

Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA

Accord Healthcare receives positive CHMP opinion for IMULDOSA®, a ustekinumab biosimilar to Stelara®